Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-384
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABT-384 is a potent and selective small molecule inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1), an enzyme responsible for the regeneration of active cortisol from cortisone in several tissues. By inhibiting HSD-1, ABT-384 blocks the local production of cortisol, which has been hypothesized to contribute to cognitive impairment in conditions such as Alzheimer's disease. The drug was developed by AbbVie and has been investigated primarily for the treatment of Alzheimer's disease. Despite achieving complete brain HSD-1 inhibition in clinical trials, it did not demonstrate symptomatic improvement in patients with mild-to-moderate Alzheimer's disease and development was discontinued after phase II studies[1][4][6][7].
02
Targets
HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)
Beyond the preview
Go deeper on ABT-384.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABT-384.